Phio Pharmaceuticals Corp. (PHIO): Capital Expenditures
$12.0K
Year ended 2025-12-31
$7.0K
Trailing 12 months to 2026-06-30
-53.7%
3-year compound annual growth
-8.8%
5-year compound annual growth
-14.4%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.0K | n/m | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $1.0K | -80.0% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $5.0K | -95.9% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $121.0K | +137.3% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $51.0K | +168.4% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $19.0K | -73.6% | 2022-03-22, From 2020-01-01 |
| 2019-12-31 | $72.0K | n/m | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | $5.0K | -97.5% | 2020-03-26, From 2018-01-01 |
| 2017-12-31 | $203.0K | n/m | 2019-03-27, From 2017-01-01 |
| 2016-12-31 | $4.0K | -93.0% | 2018-03-26, From 2016-01-01 |
| 2015-12-31 | $57.0K | -40.0% | 2017-03-30, From 2015-01-01 |
| 2014-12-31 | $95.0K | +21.8% | 2016-03-30, From 2014-01-01 |
| 2013-12-31 | $78.0K | +420.0% | 2015-03-30, From 2013-01-01 |
| 2012-12-31 | $15.0K | n/a | 2014-03-28, From 2012-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $12.0K | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $1.0K | -91.7% |
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $0 | -100.0% |
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | $14.0K | n/a |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $5.0K | -64.3% |
| Gain Therapeutics, Inc. (GANX) | 2024-12-31 | $22.5K | +46.5% |
| Faeth Therapeutics, Inc. (FTH) | 2025-12-31 | $16.0K | -89.0% |
| Lftd Partners Inc. (LIFD) | 2025-12-31 | $121.6K | -61.2% |
| Immunic, Inc. (IMUX) | 2025-12-31 | $161.0K | -39.0% |
Compare PHIO, EMMA, MBRX, NXTS side by side · Screen every company in Pharmaceutical Preparations ↗